LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dyslipidemias
Conditions
Dyslipidemias
Trial Timeline
Sep 3, 2019 → Mar 31, 2021
NCT ID
NCT04052594About LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC
LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC is a phase 1 stage product being developed by Eli Lilly for Dyslipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT04052594. Target conditions include Dyslipidemias.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04052594 | Phase 1 | Completed |
Competing Products
15 competing products in Dyslipidemias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY3202328 + Placebo + Atorvastatin + Simvastatin | Eli Lilly | Phase 1 | 33 |
| Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mg | Yuhan | Approved | 85 |
| LY3885125 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3561774 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3561774 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2484595 + Placebo + Atorvastatin | Eli Lilly | Phase 2 | 52 |
| Atorvastatin + Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 84 |
| Vupanorsen + Placebo | Pfizer | Phase 2 | 51 |
| Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 84 |
| GWP42003 + GWP42003 + GWP42004 + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| ARO-APOC3 | Arrowhead Pharmaceuticals | Phase 2 | 49 |
| ARO-ANG3 + sterile normal saline (0.9% NaCl) | Arrowhead Pharmaceuticals | Phase 1 | 30 |